The Trithorax and Polycomb groups of chromatin regulators are critical for cell-lineage specification during normal development; functions that often become deregulated during tumorigenesis. As an example, oncogenic fusions of the Trithorax-related protein mixed lineage leukemia (MLL) can initiate aggressive leukemias by altering the transcriptional circuitry governing hematopoietic cell differentiation, a process that requires multiple epigenetic pathways to implement. Here we used shRNA screening to identify chromatin regulators uniquely required in a mouse model of MLL-fusion acute myeloid leukemia, which revealed a role for the Polycomb repressive complex 2 (PRC2) in maintenance of this disease. shRNA-mediated suppression of PRC2 subunits Eed, Suz12 or Ezh1/Ezh2 led to proliferation arrest and differentiation of leukemia cells, with a minimal impact on growth of several non-transformed hematopoietic cell lines. The requirement for PRC2 in leukemia is partly because of its role in direct transcriptional repression of genes that limit the self-renewal potential of hematopoietic cells, including Cdkn2a. In addition to implicating a role for PRC2 in the pathogenesis of MLL-fusion leukemia, our results suggest, more generally, that Trithorax and Polycomb group proteins can cooperate with one another to maintain aberrant lineage programs in cancer.
INTRODUCTION
Cellular identity in multicellular organisms is reinforced by masterregulatory transcription factors in concert with chromatin modifying activities. A major epigenetic regulatory axis maintaining the 'ON' or 'OFF' state of transcription is composed of the Trithorax and Polycomb groups of chromatin regulators, respectively (for review see 1, 2 ). First discovered in Drosophila based on their antagonistic regulation of homeotic phenotypes, 3, 4 Trithorax and Polycomb group proteins have emerged as key regulators of transcriptional programs underlying embryonic development, tissue homeostasis and the pathogenesis of several human diseases, including cancer. 5 Trithorax and Polycomb group proteins possess diverse regulatory activities directed toward chromatin, including lysine methyltransferase, ubiquitin ligase, chromatin remodeling ATPase, as well as a host of histone-binding modules. 1, 2 Polycomb repressive complex 2 (PRC2) mediates gene silencing through catalysis of histone H3K27 methylation. 6 --8 PRC2 is minimally comprised of two essential non-catalytic subunits, Eed and Suz12, as well as one of two SET domain containing methyltransferase subunits, Ezh1 or Ezh2. 6 --9 Recruitment of PRC2 generally occurs at CpG-rich promoter sequences in the genome, mediated through an assortment of protein --protein and protein --RNA interactions to establish localized domains of H3K27 methylation. 10, 11 This histone mark serves as a docking site for other Polycomb complexes, which exert a repressive effect on transcription. 6 A key function of PRC2 in mammals is to regulate stem cell function, where it can promote self-renewal through direct repression of pro-differentiation genes. 12 --14 Additionally, several lines of evidence link the function of PRC2 to the pathogenesis of human cancer. Ezh2 is overexpressed in many different malignancies and mutations that elevate its tri-methyltransferase activity are found in subtypes of lymphoma, together suggesting a pro-tumorigenic role for this complex. 5,15 --17 However, Ezh2 loss-of-function mutations have also been observed in myelodysplastic syndrome (MDS), suggesting a tumor suppressor function in certain cellular contexts. 18, 19 Interestingly, Ezh2 loss-offunction mutations are rarely observed in primary acute myeloid leukemia (AML), suggesting that a role for PRC2 in myeloid cancer might be highly dependent on cellular and genetic context (Ross Levine, personal communication).
In mammals, a major class of Trithorax-group genes belongs to the mixed lineage leukemia (MLL) subfamily. MLL (also known as MLL1) encodes a histone H3K4 methyltransferase essential for hematopoietic development through maintenance of transcription of specific target genes, most notably HOX clusters. 20 Mutant forms of MLL also act as potent oncogenes in AML pathogenesis, which are generally associated with chemotherapy-resistant disease (reviewed in Krivtsov and Armstrong 21 ). MLL can often be mutated via chromosomal translocation, where the N-terminal fragment of MLL is fused to the C-terminus of one of over 50 known partner genes, with AF9 being the most common in AML. 22 MLL-AF9 acts in a gain-of-function manner via aberrant recruitment of AF9-interacting proteins to normal MLL target genes, resulting in transcriptional hyperactivation. The biological con-sequence of MLL-AF9 expression is a blockade of myeloid maturation and an enduring state of self-renewal. Coupling of MLL-AF9 expression with activating mutations in the MAP kinasesignaling pathway (e.g., NRAS G12D ), is thought to be sufficient for leukemic transformation. 23, 24 G12D leukemia and 32D myeloblasts. All shRNAs evaluated were identified from a pooled negative-selection shRNA screen reported previously. 25 MLL-AF9;Nras G12D leukemia or 32D myeloblasts were transduced with individual LMN-shRNA vectors (MSCV-miR30-shRNA-PGK-NeoR-IRES-GFP), followed by measurement of the GFP-percentage at day 2 and day 12 postinfection using a Guava Easycyte (Millipore, Billerica, MA, USA). Growth inhibition was calculated as the ratio of the GFP percentage measured at day 2 to day 12 of partially transduced cell populations. As leukemia and 32D cells grow at comparable rates in vitro (Supplementary Figure 1) , relative GFP depletion is a suitable assay for comparing growth effects in each line. represents a paradigm for understanding causality between epigenetic alterations and cancer pathogenesis.
To better define the repertoire of epigenetic regulators specifically required for maintaining MLL-fusion AML, we systematically compared the effects of suppressing chromatin regulators in a mouse model of MLL-AF9;Nras G12D AML versus nontransformed hematopoietic cell lines. Our results identify PRC2 as a highly specific requirement for the maintenance of this disease. Inhibition of PRC2 results in differentiation of leukemia cells because of anomalous upregulation of specific growthinhibitory genes, including the Cdkn2a gene products p16 G12D leukemia cultures were transduced with either experimental shRNAs from the LMN vector, or with a Ren.713 control shRNA expressed from LMN-mCherry. Experimental and control cultures were mixed at 1:1 GFP:mCherry ratio followed by transplantation of 1Â10 6 cells into secondary recipients on day 2 postinfection, before any depletion of GFP þ cells in vitro. Upon reaching terminal disease state (B15 days), as indicated by moribund appearance and whole-body bioluminescent signal, mice were killed and bone marrow was collected for flow cytometry evaluation. Using an LSRII flow cytometer, gating was performed on donor-derived leukemia populations (CD45.2 þ ) and the ratio of GFP:mCherry was measured. (b) Percentage of GFP and mCherry positivity within donorderived leukemia cells (CD45.2 þ ) derived from bone marrow at the terminal disease endpoint (B15 days following transplant). Each shRNA group included five mice. (c, d) Tet-on competent MLL-AF9;Nras G12D leukemia cultures were retrovirally transduced with TRPMV-Neo constructs (pSIN-TRE-dsRed-miR30-shRNA-PGK-Venus-IRES-NeoR) followed by G418 selection (1 mg/ml for 6 days). Transduced cells were then transplanted into secondary recipient animals, followed by initiation of doxycycline administration after 1 --2 days. Mice were monitored thereafter by bioluminescent imaging (IVIS Spectrum system; Caliper LifeSciences, Hopkinton, MA, USA) and for differences in overall survival. Bone marrow from leukemic mice at terminal disease stage was analyzed by flow cytometry for the percentage of dsRed þ /shRNA þ cells in donorderived (CD45.2 þ ) leukemia populations. Each shRNA group contained 8 --10 mice. (c) Kaplan --Meier survival curves of mice transplanted with Tet-on competent MLL-AF9;Nras G12D leukemia cells transduced with the indicated shRNAs in the TRMPV-Neo vector. 32 Statistical significance was calculated by using log-rank test comparing with shRen control group; *Po0.05; **Po0.0001. 
RESULTS AND DISCUSSION
We previously reported an shRNA screening strategy for identifying epigenetic regulators needed for growth of a murine model of MLL-AF9;Nras G12D -driven AML, which revealed the bromodomaincontaining protein Brd4 as a dependency in this disease. 25 This screen identified several additional chromatin regulators as necessary for leukemia growth, however, the disease specificity and in vivo relevance were unexplored. 25 To address this, we compared the impact of shRNAs capable of suppressing growth of leukemia with their effect on growth of 32D, an immortalized, non-leukemic myeloid cell line. A number of positive control shRNAs targeting Polr2b, Rpl15, Myc, Rpa1, Rpa3 and Pcna were included, which all suppressed growth comparably in both 32D and leukemia contexts (Figure 1a) . The most leukemia-specific growth requirement identified was Men1, encoding Menin, a known cofactor for MLL-AF9 with a well-established and highlyspecific maintenance role in this disease 26, 27 ( Figure 1a) . Based on the criteria of potent leukemia growth inhibition with neutral effects in 32D, our analysis identified three additional candidates, Eed, Suz12 and Kdm1a (Figure 1a) . shRNAs targeting these genes also did not affect the growth of non-transformed G1E and EML hematopoietic cell lines, 28, 29 confirming their leukemia-specific requirement (Figures 1b and c) . To rule out off-target effects, we retrieved all shRNAs designed to target Eed, Suz12, Men1 and Kdm1a from the original library and compared their knockdown efficiency with their relative impact on AML proliferation ( Figures  1d --i, Supplementary Figure 2) . In all cases the degree of knockdown correlated with the level of growth inhibition, suggesting that the observed effects with shRNA were because of knockdown of their predicted target.
As Eed and Suz12 both encode integral subunits of PRC2, 7, 8, 30, 31 we next investigated the role of other components in this complex. The methyltransferase subunit of PRC2 can be either Ezh1 or its close homolog Ezh2, with both genes being required to maintain the total cellular content of H3K27 methylation. 9 Although individual shRNAs targeting Ezh1 or Ezh2 displayed only weak or no growth inhibitory effects (data not shown), coexpression of the two most potent Ezh1 and Ezh2 shRNAs together led to synergistic inhibition of MLL-leukemia proliferation, indicating a requirement for the PRC2 catalytic subunit (Figure 1j, Supplementary Figure 3) . Importantly, knockdown of Eed or Suz12 alone was sufficient to deplete total H3K27me3 levels, consistent with prior reports of these core subunits being essential for PRC2 activity 30, 31 (Figures 1k and l) . Interestingly, there appears to be a threshold of B80% knockdown of Eed or Suz12 that results in severe depletion of total H3K27me3 levels and ensuing effects on leukemia growth (Figures 1g, h, k and l). Together, these data suggest that MLL-AF9;Nras G12D leukemia is reliant on PRC2 for rapid proliferation in culture.
We next examined whether the leukemia-specific requirements observed in vitro were also relevant in vivo. First, we performed a competitive transplant assay where MLL-AF9;Nras G12D leukemia cells transduced with experimental or control shRNAs were mixed and evaluated for their relative ability to initiate disease in secondary recipient mice (Figure 2a ). Leukemia cells transduced with shRNAs targeting Men1, Eed or Suz12 were outcompeted by control cells during leukemia growth in vivo, as indicated by the depletion of GFP positivity following 10 days of disease expansion (Figure 2b) . Interestingly, although Kdm1a knockdown inhibited leukemia proliferation in vitro, this level of knockdown had a negligible impact on proliferation in vivo (Figure 2b ). This observation was confirmed with multiple independent Kdm1a shRNAs (data not shown), suggesting the requirement for this specific gene might be augmented under tissue culture conditions.
To further confirm that Eed and Suz12 have an important role during leukemia progression in vivo, we made use of doxycyclineinducible shRNA vectors to deliver knockdown following disease engraftment into recipient animals. 32 As compared with controls, doxycycline-induced Men1, Eed and Suz12 knockdown led to inhibition of leukemia expansion in vivo associated with a statistically significant, albeit modest, survival benefit ( Figures  2c and d ). Similar to results described above, as the leukemia expanded in vivo, cells expressing Men1, Eed or Suz12 shRNA were outcompeted by shRNA-negative cells, as indicated by depletion of shRNA/dsRed positivity within the terminal leukemia burden (Figures 2f and g ). These experiments further support PRC2 being required for rapid leukemia expansion in vivo and not simply for disease engraftment.
A hallmark of MLL-fusion AML is the inappropriate blockade of myeloid differentiation and aberrant self-renewal capacity present within leukemia stem cell subpopulations, which can be prospectively identified as a c-Kit/Cd117 expressing subpopulation. 33, 34 Based on the known role of PRC2 in supporting selfrenewal in other stem-cell contexts, 12 --14 we considered whether a similar function might be relevant in leukemia. Indeed, shRNAmediated suppression of Eed or Suz12 in MLL-AF9;Nras Figure 3b) , as well as a morphological transition toward a differentiated macrophage-like appearance ( Figure 3c) . As a control, we verified that a differentiation-like phenotype was also induced upon suppression of MLL-AF9 or Menin, consistent with prior findings 26, 35, 36 (Figures 3a --c) . Finally, we performed expression microarrays of leukemia cells transduced with Eed or Suz12 shRNA. Gene Set Enrichment Analysis of these data revealed a systematic downregulation of genes known to be highly expressed in leukemia stem cells and upregulation of macrophage-specific genes 37 ( Figure 3d ). Based on these findings, we conclude that PRC2, like MLL-AF9, is required to enforce the blockade of myeloid differentiation present in leukemia.
We next sought to identify the direct repression targets of PRC2 relevant to its leukemia maintenance function. To this end, we analyzed the expression microarray data described above to identify 149 genes displaying 42-fold upregulation following both Eed and Suz12 knockdown (Figure 4a ). This group of candidate PRC2 targets was further reduced to 97 based on the presence of a CpG island near the promoter region, a sequence feature strongly linked with PRC2 recruitment in the mammalian genome. 11 We next used chromatin immunoprecipitation-qPCR to further discriminate direct from indirect PRC2 targets by measuring levels of H3K27me3 in the vicinity of the promoter region, which identified 60 genes with significant enrichment (Figure 4b) . We surveyed the published literature pertaining to these genes for evidence of any known role in either (a) promoting myeloid differentiation, (b) negatively regulating stem cell self-renewal or (c) inhibiting the cell cycle or cell survival. Using these criteria, we identified Id2, 38 Perp, 39 Zmat3 40 and Cdkn2a, 41 as candidates for further evaluation (Supplementary Figure 4) .
To determine whether repression of these genes might be required for leukemia growth, we first examined the impact of retroviral overexpression of each in MLL-AF9;Nras G12D leukemia cells. Overexpression of all of the candidate genes but Perp led to growth inhibition, with the two protein products of the Cdkn2a locus, p16
Ink4a and p19 Arf displaying the greatest potency (Figure 4c) . Using flow cytometry, we found that overexpression of Id2, Zmat3, p16
Ink4a or p19 Arf all led to depletion of c-Kitpositive cells from leukemia cultures (Figure 4d ), resembling the phenotype observed upon inhibition of PRC2 (Figure 3a) . Although the collective repression of multiple downstream targets could account for the entirety of a PRC2-requirement in leukemia, we considered that a substantial contribution might be mediated by Cdkn2a repression, based on the potent phenotypes observed upon p16
Ink4a and p19 Arf overexpression. To evaluate this, we employed a validated Cdkn2a shRNA to suppress levels of both p16
Ink4a and p19 Arf and evaluated whether this influenced the PRC2 requirement for leukemia growth 42 (Supplementary Figure 5) . Indeed, shRNA knockdown of Cdkn2a rendered leukemia cells less dependent on Eed and Suz12 for rapid growth (Figure 4e) , indicating that at least one role for PRC2 in MLL-fusion AML is to maintain low levels of p16
Ink4a and p19 Arf to permit leukemia proliferation.
Our findings support a role for PRC2 in MLL-AF9;Nras G12D AML to prevent differentiation and sustain aberrant self-renewal. As such, this study illustrates how Trithorax and Polycomb group regulators can together support a pathological cellular state in cancer. The repressive function of PRC2, in this case directed towards genes that restrict self-renewal like Cdkn2a, acts complementary to MLL-AF9, which directly activates expression of genes that promote self-renewal like HoxA9. Importantly, inhibition of PRC2 has only a minimal impact on the expression of well-established direct target genes of MLL-AF9, which also harbor minimal levels of H3K27 methylation at their promoters (Supplementary Figure 6) , suggesting it is the segregation of each pathway to distinct target sites in the genome which can enable a complementary function in this disease. This is in stark contrast to the antagonism generally seen between Trithorax and Polycomb proteins when they intersect at common target genes. It should be noted that the presence of mutant Nras might influence the collaborative actions of MLL-AF9 and PRC2 seen in this experimental system. Although NRAS mutations commonly cooccur with MLL-translocations, 24 the presence of alternative cooperating mutations (e.g., FLT3 ITD ) might impose a different degree of PRC2 dependency, an issue that could be addressed in the future by examining other genetically-engineered models of MLL-fusion leukemia.
The Polycomb repressive complex 1 (PRC1) subunit Cbx8 has recently been reported to interact directly with AF9, thereby supporting the function of MLL-AF9 in leukemogenesis. 43 In this case, Cbx8 functions independently of the repressive PRC1 complex, acting instead to support transactivation by MLL-AF9. 43 Although this mechanism is entirely distinct from the repressive function of PRC2 described here, both studies highlight collaboration between Trithorax and Polycomb proteins in the setting of cancer, which may represent an emerging model of epigenetic dysfunction driving tumorigenesis.
A recurring theme in the study of cancer epigenetics is the duality of many chromatin regulators in displaying both tumorpromoting and tumor-suppressing activities, depending on cellular context. For example, the inactivating mutations of EZH2 seen in MDS suggest a tumor-suppressor function in this disease, 18, 19 in contrast to the tumor-maintenance role in MLLfusion AML described here and that observed previously in several human AML cell lines. 44, 45 The repressive landscape of H3K27me3 is known to be both plastic as well as heritable in nature, mediated by the ability of Eed to recruit PRC2 to sites of preexisting H3K27me3. 46, 47 Based on these epigenetic properties, we speculate that myeloid cells can select for, and thereafter maintain, a global configuration of repressive H3K27me3 that complements the specific genetic lesions driving leukemic transformation. Consistent with such a model, we see significant differences in levels of H3K27me3 at many promoters when comparing MLLfusion leukemia to 32D cells (Supplementary Figure 7) , suggesting variable patterns of PRC2 recruitment in different myeloid contexts. An important feature of the mouse model used here is that an aggressive disease is initiated by high-level expression of two potent oncogenes, a context that would be expected to differ demonstrably from the evolution of MDS. 48 One possibility is that PRC2 plays a maintenance role in primary AML by buffering Flow cytometry analysis of cell surface levels of c-Kit/Cd117 and Mac-1/Cd11b. MLL-AF9 was suppressed as a positive control using a TET-off system, 35 following 5 days of 1 mg/ml doxycycline treatment. Untreated TET-off leukemia cells were used a negative control. Men1, Eed and Suz12 LMN-shRNAs were transduced into MLL-AF9;Nras G12D leukemia cultures, with cell-surface staining and flow-cytometry analysis performed on day 7 postinfection. As the average infection efficiency was B20%, shRNA þ /GFP þ cells were compared with shRNAÀ/GFPÀ within each culture as an internal negative control. (c) Light microscopy of May --Grunwald/Giemsa-stained MLL-AF9;Nras G12D leukemia cells under the same experimental condition used in a, b, except G418 was administered to LMN-transduced cells following infection to select for shRNA þ /GFP þ cells. Imaging was performed using Â 40 objective. Representative images of three biological replicates are shown. (d) Gene Set Enrichment Analysis of microarray data obtained from leukemia cells transduced with Eed and Suz12 LMN-shRNAs, 5 days postinfection/G418 selection. FDR q-value, false discovery rate q-value; NES, normalized enrichment score. All error bars shown represent s.e.m. against the stress imposed by the presence of two potent oncogenes. 41 This is suggested by our identification of Cdkn2a as a key downstream repression target of PRC2, a finding also seen in a prior study examining PRC2 function in human AML cell lines. 45 Nevertheless, as a knockout of EZH2 in adult mouse bone marrow does not significantly interfere with hematopoietic output, the possibility exists for PRC2 to be a therapeutic target in MLL-fusion AML. 49 Understanding how such epigenetic dependencies 
